Molecular Diagnostics of Infectious Disease 2020-2024: Strategic Situation Analysis and Impact of COVID-19 - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Molecular Diagnostics for Infectious Disease By Syndrome, Plex, Place and by Country. With COVID-19 Impact & Forecasting/Analysis, and Executive Guides and Customization 2020 - 2024" report has been added to ResearchAndMarkets.com's offering.

COVID-19 drives a surge in demand but what is the long term impact? The microbiology lab may disappear while multiplex takes center stage.

The Molecular Diagnostics - Infectious Disease sector of the clinical diagnostics industry is poised for record growth. A market that just keeps on growing but is spiking as an enormous C19Dx demand sweeps over the globe. Find out what the numbers are in this informative report. And find out about the exciting developments in multiplex assays which threaten to change diagnosis and treatment while limiting the threat of antimicrobial drug resistance.

Infectious disease testing directly benefits from the explosion in biotechnology, especially genomics. A range of dynamic trends is pushing market growth and company valuations.

Trends like:

• Multiplex testing
• Pathogen evolution and pandemics
• Biotechnology advances in genetics
• Climate change
• Globalization
• The rise of rapid testing

Exciting technical developments especially in the seesaw between nucleic acid testing and immunoassay, hold the promise of a dynamic, growing and evolving world market that holds the promise of diagnostics taking the lead in infectious disease eradication.

The report has hundreds of pages of information including a complete list of Current 2020 United States Medicare Fee Payment Schedules to help sharpen your pricing. The report includes detailed breakouts for 15 Countries and 4 Regions.

Key Topics Covered:

Molecular Diagnostics of Infectious Disease - Strategic Situation Analysis and Impact of COVID-19

• Guide for Executives, Marketing, Sales and Business Development Staff
• Guide for Management Consultants and Investment Advisors

1. Introduction and Market Definition

2. The Infectious Diseases - Market Analysis by Disease

2.1 HIV - Human Immunodeficiency Virus (AIDS)

2.2 HBV - Hepatitis B

2.3 HCV - Hepatitis C

2.4 HPV - Human papillomavirus

2.5 Influenza

2.6 CTGC - Chlamydia/Gonorrhoea

2.7 Tuberculosis

2.8 MRSA - Methicillin-resistant Staphylococcus aureus

2.9.1 FDA Approved MDx Tests for VRE

2.10 Blood Screening

2.11 COVID-19

2.12 Pandemic Diagnostics

3. Industry Overview

3.1 Players in a Dynamic Market

3.2 The Clinical Laboratory Market Segments

3.3 Industry Structure

3.3.1 Hospital Testing Share

3.3.2 Economies of Scale

3.3.2.1 Hospital vs. Central Lab

3.3.3 Physician Office Lab's

3.3.4 Physician's and POCT

3.4 Profiles of Key MDx Companies

• Abbott Diagnostics
• Accelerate Diagnostics
• Ador Diagnostics
• Akonni Biosystems
• Alveo Technologies
• Applied BioCode
• Atlas Genetics
• Aus Diagnostics
• BD Diagnostics
• Beckman Coulter
• Biocartis
• bioMrieux
• Bio-Rad Laboratories
• Bosch Healthcare Solutions GmbH
• Cepheid
• Chembio
• Curetis
• Diagenode Diagnostics
• DiaSorin
• Eiken Chemical
• Fusion Genomics
• Genedrive
• GenePOC Diagnostics
• GenMark Dx
• Grifols
• Hologic
• Illumina
• Inflammatix
• Janssen Diagnostics
• Karius
• Lexagene
• Luminex
• Mbio Diagnostics
• Meridian Bioscience
• Mesa Biotech
• Mobidiag
• Nanomix
• Oxford Nanopore Technologies
• Panagene
• Primerdesign
• Prominex
• Qiagen
• Quantumdx
• Quidel
• Roche Molecular Diagnostics
• Seegene
• Siemens Healthineers
• T2 Biosystems
• Thermo Fisher
• Veramarx
• XCR Diagnostics

4. Market Trends

4.1 Factors Driving Growth

4.1.1 New Genotypes Creating New Markets

4.1.2 Aging Population a Boon for All Diagnostics

4.1.3 Developing World Driving ID Dx Growth

4.1.4 Point of Care - Why Centralization is Losing Steam

4.1.5 Self Testing

4.1.6 The Need for Speed

4.2 Factors Limiting Growth

4.2.1 Lower Costs

4.2.2 Infectious Disease is Declining

4.2.3 Wellness Hurts

4.2.4 Economic Growth improves Living Standards

4.3 Instrumentation and Automation

4.3.1 Instruments Key to Market Share

4.3.2 The Shrinking Machine

4.3.2 Multiplex, Point of Care and The Speed Factor

4.4 Diagnostic Technology Development

4.4.1 The Sepsis Testing Market - A New Direction?

4.4.2 POCT/Self Testing as a Disruptive Force

4.4.3 The Genetics Play - One Test for All Known Infections

4.4.4 Antibiotic Resistance Genes - Simplifying Diagnostics

5. Molecular Dx - Infectious Disease Recent Developments

6. The Global Market for Molecular Diagnostics Infectious Disease

6.1 Global Market Overview by Country

6.2 Global Market by Syndrome - Overview

6.3 Global Market by Plex - Overview

6.4 Global Market by Place - Overview

7. Global MDx Infectious Disease Markets - By Syndrome

7.1 Respiratory

7.2 Gastrointestinal

7.3 Blood

7.4 Meningitis/Encephalitis

7.5 Sexually Transmitted Disease

7.6 Other

8. Global MDx Markets for Infectious Disease - by Plex

8.1 Single Plex

8.2 Duplex

8.3 Triplex

8.4 Multiplex Technology

9. Global MDx Infectious Disease Markets - by Place

9.1 Hospital Lab

9.2 Outpatient Lab

9.3 POC

9.4 Other Technology

Appendices

• United States Medicare System: 2020 Clinical Laboratory Fees Schedule
• COVID-19 Approved Assays

For more information about this report visit https://www.researchandmarkets.com/r/fg90pe

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.